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All coronaviruses encode a small hydrophobic envelope (E) protein, which mediates viral assembly and morphogenesis by an unknown
mechanism. We have previously shown that the E protein from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) forms cation-
selective ion channels in planar lipid bilayers (Wilson, L., McKinlay, C., Gage, P., Ewart, G., 2004. SARS coronavirus E protein forms cation-
selective ion channels. Virology 330(1), 322–331). We now report that three other E proteins also form cation-selective ion channels. These E
proteins were from coronaviruses representative of taxonomic groups 1–3: human coronavirus 229E (HCoV-229E), mouse hepatitis virus (MHV),
and infectious bronchitis virus (IBV), respectively. It appears, therefore, that coronavirus E proteins in general, belong to the virus ion channels
family. Hexamethylene amiloride (HMA) – an inhibitor of the HIV-1 Vpu virus ion channel – inhibited the HCoV-229E and MHV E protein ion
channel conductance in bilayers and also inhibited replication of the parent coronaviruses in cultured cells, as determined by plaque assay.
Conversely, HMA had no antiviral effect on a recombinant MHV with the entire coding region of E protein deleted (MHVΔE). Taken together,
the data provide evidence of a link between inhibition of E protein ion channel activity and the antiviral activity of HMA.
© 2006 Elsevier Inc. All rights reserved.Keywords: E protein; Coronavirus; Ion channel; Mouse hepatitis virus (MHV); Human coronavirus 229E (HCoV-229E); Infectious bronchitis virus (IBV);
Amiloride; Hexamethylene amiloride (HMA); Antiviral compoundIntroduction
Coronaviruses (order Nidovirales, family Coronaviridae,
genus Coronavirus (Gonzalez et al., 2003)), are enveloped,
single-stranded, positive-sense RNA viruses with a genome of
about 30 kb. All coronaviruses encode the envelope (E) protein,
which is a small hydrophobic membrane protein. While the
exact functions and mechanisms of the coronavirus E protein
are yet to be fully characterized, the E protein has been shown to
be important for coronavirus replication, with roles in viral
assembly and morphogenesis (Fischer et al., 1998; Kuo and⁎ Corresponding author. ANU Medical School, Pathology Building 10, 6th
floor, The Canberra Hospital, Woden ACT 2606, Australia. Fax: +61 2 6244
3092.
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doi:10.1016/j.virol.2006.05.028Masters, 2003; Ortego et al., 2002). In general, while the
different coronavirus E proteins share little sequence homology,
their basic structures are similar (Shen et al., 2003). All E
proteins are small hydrophobic proteins, with a single putative
transmembrane α-helix and a hydrophilic C terminal domain
(Shen et al., 2003; Siddell, 1995).
Previously, we demonstrated that the E protein from Severe
Acute Respiratory Syndrome coronavirus (SARS-CoV) forms
cation-selective ion channels in planar lipid bilayers that are
about 10-fold more selective for Na+ than for K+ ions. The first
40-amino-acid residues of SARS-CoV E protein, encompassing
the putative transmembrane (TM) domain, were sufficient for
formation of ion channels with similar properties to the full-
length peptide (Wilson et al., 2004). This was the first
coronavirus E protein shown to belong to the virus ion channel
family. Madan et al. (2005) have recently reported that the
MHV E protein induces membrane permeability changes in E.
Fig. 1. Western blot analysis of HCoV-229E (group 1), MHV (group 2) and IBV
(group 3) synthetic E peptides. Lane 1: molecular weight marker, (A) lane 2:
HCoV-229E E peptide, (B) lane 2: MHV E peptide. (C) Lane 2: IBV E peptide.
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viroporin-like activity (Madan et al., 2005). Therefore, it is
possible that ion channel formation is a function common to all
coronavirus E proteins.
It is not yet known whether the SARS-CoV E protein ion
channel activity has an important role in coronavirus replication.
However, for the two best characterized virus ion channels –M2
protein from influenza A and Vpu from HIV-1 – ion channel
activity has been strongly linked to roles in the virus's life cycles
by studies with mutants and channel blocking drugs (Hout et al.,
2005a, 2005b; Pinto et al., 1992; Sakaguchi et al., 1996;
Schubert et al., 1996). The M2 ion channel activity is inhibited
by amantadine and some of its derivatives, and these are
currently used in the clinical treatment of influenza A infections
(Fleming, 2001; Pinto et al., 1992). We have demonstrated that
the Vpu ion channel activity in planar lipid bilayers is blocked by
the amiloride derivate HMA, and that HMA also inhibits
replication of HIV-1 in cultured human macrophages (Ewart
et al., 2002, 2004). For some other viral ion channels, inhibitors
have also been discovered (Griffin et al., 2003; Pavlovic et al.,
2003; Premkumar et al., 2005; Premkumar et al., 2004),
although evidence of antiviral activity of the compounds has
not yet been published. The goals of our research were,
therefore, to identify other coronavirus E protein ion channels,
find blockers of the channel activity and characterize the effect
of channel-blocking compounds on viral replication.
In this paper, we report that E proteins from three
coronaviruses – human coronavirus 229E (HCoV-229E, a
group 1 coronavirus); mouse hepatitis virus (MHV, group 2), and
infectious bronchitis virus (IBV, group 3) – have ion channel
activity in planar lipid bilayers. Furthermore, HCoV-229E and
MHV E protein ion channel conductance was inhibited by the
amiloride derivative HMA, but not by amiloride itself. Channel-
blocking activity correlated with inhibition of replication of
these viruses, as demonstrated by plaque assays. Conversely,
HMA had no antiviral activity against the recombinant MHV
with the entire E protein deleted, indicating that E protein is the
possible antiviral target.
Results
Peptide characterization
Synthetic peptides corresponding to the E proteins of HCoV-
229E, MHV, and IBV, were prepared using solid phase
chemistry. The full-length peptides, with predicted molecular
weights of 9092.9, 9660.0, and 10475.4 Da, respectively, were
excised from SDS-polyacrylamide gels and purified as described
in Materials and methods. Western blot analysis of the purified
peptides (Fig. 1) showed that all three preparations contained
discrete protein bands electrophoresing at approximately the
expected size of the full-length products and recognized by the
appropriate peptide-specific antibodies. HCoV-229E E protein
ran as a single discrete band at about its expected molecular
weight, indicating that the sample contained mostly full-length
protein and did not contain significantly truncated products. The
MHVand IBV E samples both yielded discrete doublet bands onthe blots, with in each case the smaller of the two bands running
at about the expected molecular weight. It is possible that, due to
their highly hydrophobic nature, the proteins may electroporese
more slowly than expected, and it may be the larger of the two
bands that corresponds to the full-length (or at least very near
full-length) protein and the smaller band represents a truncated
species. The MHV E protein was detected with an antibody that
recognizes an epitope within the first 19 N-terminal amino acids
(referred to as, anti-MHV EN). Since, peptide synthesis
proceeds from the C-terminus to the N-terminus and because it
would require about 6-amino-acid residues to form an epitope to
react with the anti-MHVEN antibody, theWestern blot indicates
the smaller immunoreactive peptide would be truncated at the N-
terminus by maximally about 13 amino acids. As predicted from
MHV E protein hydropathy plot, the E protein N-terminus
consists of about a 14-amino-acid hydrophilic region so even the
296 L. Wilson et al. / Virology 353 (2006) 294–306smaller of the two immunoreactive species would contain an
intact TM putative ion channel domain. The IBV E protein also
ran as a doublet, and again, it is likely that the larger band
represents the full-length product and the smaller band is IBV E
protein with several amino acids truncated from the N-terminus.
For all three synthetic peptides Western blots confirmed the
presence of proteins of at least sufficient length to contain the
TM putative ion channel-forming domain.
The E protein from group 1 coronavirus HCoV-229E forms
potassium preferring ion channels in planar lipid bilayers
Addition of about 3 μg of purified HCoV-229E E protein to
the CIS chamber in the planar lipid bilayer rig resulted in the
formation of ion channels in the bilayer. Fig. 2A shows typical
current trace in a solution containing a 10-fold gradient of NaCl
(500 mM CIS: 50 mM TRANS) at a range of holding potentials.
Fig. 2B shows the current–voltage (I–V) plot for this experi-
ment, which reveals a reversal potential of about +26 mV. In
nineteen similar experiments where the theoretical equilibriumFig. 2. Group 1 HCoV-229E E protein ion channel activity in planar lipid bilayers. T
The CIS chamber is earthed and the TRANS chamber was held at various potentials be
ion channel activity in 10-fold gradient of NaCl (CIS-TRANS). (B) I–V relationshi
potential (mV). C) E protein ion channel activity in asymmetrical KCl solution. (D)potential for Na+ ions was +54 mV, the average measured
reversal potential was +22 ± 7 mV (mean ± SEM). This indi-
cates that the channel is weakly selective for Na+ ions over Cl−
ions. Using ion activities in the Goldman, Hodgkin, and Katz
(GHK) equation the PNa+/PCl− ratio was calculated to be 3,
indicating that the HCoV-229E E protein ion channel is only 3
times more permeable to Na+ than Cl− ions. For these 19
experiments, the average conductance was 19 ± 4 pS, and the
maximum conductance measured was 91 pS.
Fig. 2C shows typical current traces for HCoV-229E E
protein in asymmetrical KCl solution, in this experiment the K+
ion current was observed to reverse at +42 mV (Fig. 2D). In
thirteen comparable experiments with a theoretical K+ equilib-
rium potential of +54 mV, the average measured reversal
potential was +38 ± 4 mV. By the GHK equation, HCoV-229E
E protein is 12 times more selective for K+ than for Cl− ions.
For the 13 experiments, the average conductance was 23 ± 5 pS.
The ion selectivity for HCoV-229E E protein ion channel is
thus, K+ > Na+ > Cl− and the channel is about 4 times more
permeable to K+ than to Na+ ions (Table 1).he closed state is shown as a broken line; openings are deviations from the line.
tween −100 mVand +100 mV, and the data were filtered at 100 Hz. (A) E protein
p in asymmetrical NaCl solution; average current (I) measured against holding
I–V relationship in asymmetrical KCl solution.
Table 1
Relative ion permeabilities of coronavirus E protein ion channels
Source of E
protein:
parent virus
Taxonomic
group
Relative ion permeability
P(Na+/Cl−) P(K+/Cl−) Selectivity series
HCoV-229E 1 3 12 K+ > Na+ > Cl−
MHV 2a 138 2 Na+≫ K+ > Cl−
SARS-CoVa 2b 90 9 Na+≫ K+ > Cl−
IBV 3 10 3 Na+ > K+ > Cl−
a See Wilson et al. (2004).
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that are sodium selective
MHV E protein was tested for its ability to form ion
channels in planar lipid bilayers, and experiments were done to
determine the selectivity of MHV E protein for Na+ ions over
Cl− ions and for K+ ions over Cl−. Fig. 3A shows characteristic
current traces for MHV E protein ion channel activity in
asymmetrical NaCl solution. In this experiment the ion currentFig. 3. Group 2 MHV E protein ion channel activity in plareversed at +42 mV (Fig. 3 B). In 14 equivalent experiments, the
average reversal potential was +49 ± 1 mV, which is close to the
Na+ equilibrium potential of +54 mV. Thus, the MHV E protein
ion channel is highly selective for Na+ ions and the PNa+/PCl−
ratio is 138. For the 14 experiments the conductance varied
between 235 and 7 pS, with an average conductance of
61 ± 16 pS.
Fig. 3C illustrates representative current traces of MHV E
protein ion channel activity in a 10-fold concentration gradient
of KCl. In this experiment, K+ ion flow was observed to reverse
at +25 mV (Fig. 3D), but after eleven similar experiments, the
average reversal potential was calculated to be +13 ± 6 mV,
indicating that MHV E protein ion channel is only 2 times more
selective for K+ over Cl− ions. The conductance for the 11
experiments ranged from 60 to 6 pS with an average of 18 ± 5
pS. The ion selectivity order for MHV E protein ion channel
was Na+ ≫ K+ > Cl−, with the channel being about 69 times
more permeable to Na+ than K+ ions. Thus, the MHV E protein
ion channel distinguishes between monovalent cations and is
highly selective for Na+ ions (Table 1).nar lipid bilayers, as described in the legend to Fig. 2.
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prefer sodium
IBV E protein also forms ion channels in planar lipid bilayers
and experiments conducted in NaCl and KCl solutions
demonstrated that IBV E protein channels have a slight
preference for Na+ ions over K+ ions, similar to E protein
channels from the group 2 coronaviruses MHVand SARS-CoV
(Wilson et al., 2004). Fig. 4A shows typical current traces of
IBV E protein ion channel conductance in asymmetrical NaCl
solution. In this experiment, the Na+ ion flow was observed to
reverse at +30 mV (Fig. 4B). In 13 independent experiments,
the average reversal potential was +36 ± 5 mV and the IBV E
protein PNa+/PCl− ratio was 10. For the 13 experiments, the
conductance was variable, the highest conductance measured
was 77 pS, with an average conductance of 24 ± 5 pS. The I–V
relationship for the IBV E protein in NaCl solution was
nonlinear, indicating rectification of the ion channel. The
channel conductance was smaller when the TRANS chamber
was held at positive potentials relative to the CIS chamber than
when the polarity was reversed.Fig. 4. Group 3 IBV E protein ion channel activity in planTypical current traces for IBV E protein in asymmetric KCl
solution are shown in Fig. 4C; the I–V plot indicates that the K+
ion flow reversed at +28 mV (Fig. 4D). In 20 equivalent
experiments, the average reversal potential was +22 ± 3 mV,
thus, the IBV E protein was only 3 times more permeable to K+
than Cl− ions. The average conductance for the 20 experiments
was 22 ± 6 pS. Thus, the IBV E protein ion selectivity series is
Na+ > K+ > Cl− and the channel is about 3 times more selective
for Na+ than K+ ions (Table 1). Rectification of the IBV E
protein channel was not seen in KCl solutions.
We currently do not have an explanation as to why the IBV
channel shows rectification in Na+ but not K+ solutions.
Rectification indicates that ions flow more readily through the
channel in one direction than the other and the mechanism by
which this is achieved in IBV E protein channels is likely to be
related to specific properties of the protein quaternary structure
forming the gate and selectivity filters of the channel. The in
vivo significance of a rectifying channel is that ion conductance
will occur preferentially in one direction, i.e., extracellular–
intracellular, or vice versa, which could have important
implications for the physiological functions of the channel.ar lipid bilayers, as described in the legend to Fig. 2.
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conductance
We have previously shown that ion channel conductance in
planar lipid bilayers is dependent on addition of channel-
forming peptides and is not due to addition of solvent or buffers
alone (Ewart et al., 1996; Premkumar et al., 2004; Wilson et al.,
2004). To demonstrate that the ion channel activities we were
observing were specifically due to the HCoV-229E or MHV E
proteins, rather than a contaminant in samples, purified epitope-
specific antibodies recognizing these proteins were utilized. In
some previously published cases, such antibodies have been
shown to inhibit ion channel activity directly in bilayer
experiments. This inhibition depends on binding of the antibody
to an exposed epitope and either physical blocking of the ion
channel by the antibody or induction of a conformational
change in the ion channel structure that inactivates it. However,
for many antibodies, simple binding of the antibody may not be
sufficient to inactivate the target ion channel. So alternatively,
the antibodies can be used to remove the ion channel-forming
peptide from solution (Ewart et al., 1996; Melton et al., 2002).
Addition of between 2 and 7 μg of affinity purified antibody,
that recognizes the HCoV-229E C-terminal end of the TM
domain (anti-HCoV-229E E antibody), to the CIS (n = 8
experiments) or TRANS (n = 12) chambers did not noticeably
reduce the HCoV-229E E protein ion channel conductance (data
not shown). However, when this antibody was used to remove
HCoV-229E E protein from solutions (using a Seize X protein AFig. 5. Antibody treatment of MHV E protein ion channel activity in planar lipid bilay
protein ion channel activity before addition of antibody and (2) after addition of anti-
before addition of antibody and (4) after addition of anti-MHV EN antibody to the TR
the MHV E protein ion channel after addition of the anti-MHV EN antibody to the C
anti-MHV C terminal 47–67 antibody was used.immunoprecipitation kit) samples of the remaining solution did
not form ion channels, even after prolonged periods of stirring
for over 15 min (n = 5, results not shown). Depletion of the
HCoV-229E E protein from the samples was confirmed by
Western blot analysis using the anti-HCoV-229E E polyclonal
antibody (data not shown). In contrast, samples containing the
purified synthetic HCoV-229E E protein always resulted in ion
channel conductance within 15 min of the addition of the
peptide to the CIS chamber. Hence, the immunoprecipitation
experiments confirmed that the ion channel conductance
observed after addition of the purified synthetic HCoV-229E
E protein to planar lipid bilayers was dependent on presence of
the full-length HCoV-229E E protein.
In the case of the MHV E protein, an antibody directed to the
E protein first 19 amino acids of the N-terminus (anti-MHV EN
antibody) significantly inhibited ion channel conductance when
added to the CIS chamber (P≪ 0.01; n = 5, T test to test the
difference between the means). These data confirm that the
channel-forming species in the samples was the MHV E protein
(Fig. 5A1–2). Conversely, addition of the anti-MHV EN
antibody to the TRANS chamber did not affect channel
conductance (Fig. 5A3–4). This result indicates that the MHV
E protein inserts in the bilayer in an orientation-specific manner
with the N-terminal domain facing the CIS chamber. Since, the
anti-MHV EN antibody significantly inhibited MHV E protein
ion channel activity it confirms that the ion channel-forming
species contains the MHV E protein N-terminus and is thus
likely to be full-length peptide. Another MHV E antibody, theers. (A) Representative current traces at holding potential of −40 mV. (1) MHV E
MHV EN antibody to the CIS chamber. (3) MHV E protein ion channel activity
ANS chamber. (5) Normalized average current (percent pre-antibody current) of
IS or TRANS chamber. Error bars are SEM. (B) As described in panel A, except
300 L. Wilson et al. / Virology 353 (2006) 294–306anti-MHV E47–67, which does not bind directly adjacent to the
putative TM domain, did not inhibit MHV E protein ion channel
conductance when added to the CIS (n = 8) or the TRANS
chamber (n = 7) (Fig. 5B1–4). However, similarly to the HCoV-
229E E protein, the anti-MHV E47–67 antibody was used to
immunoprecipitate the full-length MHV E protein from
solution. Western blot analysis of the immunoprecipitate flow-
through demonstrated that the MHV E protein had been
removed from the solution (data not shown). Addition of the
MHV E depleted solution to the CIS chamber did not result in
ion channel formation in planar lipid bilayers (n = 5 experi-
ments), even after stirring for up to 1 h and 40 min. These data
further demonstrate that the ion channel conductance detected
was specifically due to the purified full-length MHV E protein.
Unfortunately, we were not able to obtain enough anti-IBV E
protein antiserum to conduct ion channel inhibition and
immunoprecipitation experiments with the IBV E protein.
Nevertheless, the anti-IBV E antibody directed to the C-
terminal was used to demonstrate that the synthetic purified IBV
E protein contained full-length peptide (Fig. 1).
HMA inhibits coronavirus E protein ion channels
We tested amiloride, plus its derivative, HMA for their
ability to inhibit HCoV-229E, MHV, and IBV E protein ion
channels in planar lipid bilayers. Once ion channel conductance
was detected, 100–200 μM of compound was added to the CIS
chamber while stirring to facilitate binding of the compound to
the channel. Fig. 6 demonstrates that HMA significantlyFig. 6. Coronavirus E protein ion channel activity inhibited by HMA in planar lipid
TRANS chamber was held at constant voltage. The closed state is shown as a broken l
conductance at −70 mV and (B) after addition of 100 μM of compound to the CIS c
addition of 100 μM of compound to the CIS chamber. (E) IBV E protein ion channel c
chamber. (G) Normalized average current (percent pre-drug control). Error bars arereduced HCoV-229E E protein (P ≪ 0.01, n = 5) and MHV
E protein (P ≪ 0.01, n = 5) current across the bilayer, while,
HMA had no significant affect on IBV E protein channel
conductance (P = 0.14, n = 10). Amiloride itself did not have a
significant effect on any of the coronavirus E proteins ion
channel activity (data not shown). Furthermore, addition of the
compound solvent, 50% DMSO: 50% Methanol, alone did not
affect the E protein ion channel conductances (data not shown),
indicating that channel inhibition was dependent on the
presence of HMA.
HMA inhibits MHV E protein ion channel activity in a
dose-dependent manner
To determine if HMA inhibits MHV E protein in a dose-
dependent manner, HMA was titrated on MHV E protein
channel activity in planar lipid bilayers. Fig. 7 demonstrates that,
with increasing concentration of HMA, there is a subsequent
decrease in channel activity. The percent inhibition was plotted
against the concentration of HMA and from the equation of the
line the effective concentration 50 (EC50) of HMA on MHV E
protein channel activity in bilayers was calculated to be 10.2 μM.
These data further confirm that the inhibition observed with
HMA is specifically due to addition of the compounds and not to
spontaneous reductions in the channels macroscopic conduc-
tance. Occasionally, channel activity in bilayers can go quiet in
the absence of inhibitors, this could be due to the lipids
encompassing the peptides, reduction in the macroscopic chan-
nel activity or open probability. This spontaneous reduction inbilayers in asymmetrical NaCl solution. The CIS chamber was earthed, and the
ine; openings are deviations from the line. (A) HCoV-229E E protein ion channel
hamber. (C) MHV E protein ion channel conductance at −40 mV and (D) after
onductance at −50 mVand (F) after addition of 100 μM of compound to the CIS
SEM.
Fig. 7. HMA dose-dependent inhibition of MHV E protein ion channel activity
in planar lipid bilayers in asymmetrical NaCl solution. The CIS chamber was
earthed and the TRANS chamber was held at constant voltage, −50 mV. The
closed state is shown as a broken line; openings are deviations from the line.
Scale bar is 4 pA and 200 ms. (A) Addition of increasing concentrations of
HMA to the CIS chamber of the bilayer from 10 μM to 150 μM. (B) The
measured average currents at the different concentrations of HMA were
normalized and data are shown as a percentage of the pre-drug control.
Table 2
EC50 of HMA on MHV wild-type and HCoV-229E replication in cultured
L929 cells
Coronavirus HMA EC50 Amiloride EC50
MHV wild type 3.91 μM NA
HCoV-229E 1.34 μM NA
NA = not active against viral replication.
301L. Wilson et al. / Virology 353 (2006) 294–306channel activity would not occur in a linear dose-dependent
fashion, as observed in Fig. 7A.
HMA, but not amiloride, inhibits MHV replication in cultured
cells
To determine if amiloride and HMA inhibit MHV replication
in cultured cells, they were tested for their ability to reduce the
number of MHV plaques in L929 cells without plaque overlay.
MHV infection in L929 cells without plaque overlay, results in
the newly emerged virus diffusing from the original infected cell
and starting a new plaque. Therefore, in the presence of antiviral
compound, there is a reduction in plaque number. L929 cells
were infected with MHVat a multiplicity of infection (MOI) of
0.01 and treated with various concentrations of HMA or
amiloride (see Materials and methods). The number of plaques
per well was counted, and the percent reduction in plaque
number was calculated from the no compound control. The
percent reduction was plotted against the compound concentra-tion, and the EC50 was calculated from the equation of the line.
The EC50 of HMA on MHV replication was calculated to be
3.91 μM (Table 2), in reasonable agreement with the EC50
measured in bilayer experiments. Amiloride did not inhibit
MHV replication in cultured cells (Table 2), which correlates
with the inability of amiloride to inhibit ion channel activity in
bilayers.
HMA inhibits MHV but not MHVΔE replication
To investigate the plaque phenotype of MHV in the presence
of HMA, L2 cells with a plaque overlay was used. The plaque
overlay on the MHV infected L2 cells slows diffusion of the
newly emerged virus, which then infect adjacent cells, resulting
in larger plaques than in the L929 cells. HMA was tested on
MHV infection in L2 cells at 20 μM, which is significantly
above the EC50 measured in L929 cells (Table 2), but removed
from toxicity (as determined by MTT cytotoxicity assay). To
determine if the MHV E protein was the antiviral target, HMA
was also tested for its ability to inhibit the recombinant MHV
with the entire E protein deleted (MHVΔE). MHVΔE replicates
to low titer and has a small plaque phenotype in L2 cells (Kuo
andMasters, 2003). Therefore, it is expected if compounds were
targeting the MHV E protein, replication of MHVΔE would not
be affected. Furthermore, if HMA was targeting the MHV E
protein the plaque phenotype of MHV wild-type in the presence
of HMA would be comparable to the MHVΔE small plaque
phenotype.
Fig. 8 shows that the MHV wild-type virus in mouse L2 cells
has a large plaque phenotype of about 3–4 mm in diameter in
the absence of antiviral compound (Fig. 8A1). In the presence
of 20 μM HMA the plaque size is reduced to about 1 mm
(Fig. 8A2), about the same size as the MHVΔE plaques
(Fig. 8B1). Conversely, 20 μM of amiloride did not reduce
MHV plaque size (Fig. 8A3). Moreover, none of the amiloride
derivatives tested notably inhibited MHVΔE plaque formation
(Fig. 8B1–3), indicating that MHV E protein is the probable
antiviral target.
HMA inhibits HCoV229E replication in cultured cells
HMA, which blocked HCoV-229E E protein ion channel
conductance in planar lipid bilayers, also inhibited replication of
HCoV-229E in cultured cells (Fig. 8C2). The EC50 of HMA on
HCoV-229E was calculated to be 1.34 μM (Table 2).
Additionally, amiloride, which did not block HCoV-229E E
protein ion channel current amplitude, had no antiviral activity
on HCoV-229E replication in cultured cells (Fig. 8C3).
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Previously, we reported that the SARS-CoV E protein is a
member of the viral ion channel family (Wilson et al., 2004),
and in this paper, we extend the list of known coronavirus ion
channels by three. Our data demonstrate that the E proteins from
HCoV-229E, MHV, and IBV – representative of coronavirus
taxonomic groups 1, 2, and 3, respectively – form cation-
selective ion channels in planar lipid bilayers. In the cases of
HCoV-229E and MHV, epitope-specific antibodies were used to
confirm that the channel-forming species in test samples was
indeed the purified synthetic E protein. The anti-HCoV-229E E
antibody, which binds on the C-terminal side of the transmem-
brane helix, did not inhibit channel activity in bilayers.
However, when this antibody was used to immunoprecipitate
the E protein, the residual supernatant did not form ion
channels. The anti-MHV EN antibody inhibits the MHV E ion
channel activity when added to one chamber (but not the other)
of the bilayer rig, indicating that the N-terminus of the peptide is
exposed on the CIS side of the bilayer. Further, this shows that
the peptides are aligned in a parallel, rather than antiparallel,
conformation in the presumed homo-oligomer that forms the
ion channel.
Herein, we also show that HMA inhibits the ion channels
formed by HCoV-229E andMHV E proteins (see Fig. 6). HMA,
an amiloride analogue, also blocks other viral ion channels
including; Vpu from HIV-1 (Ewart et al., 1996); p7 fromFig. 8. Plaque assay of amiloride and HMA inhibition of HCoV-229E, MHV, and MH
compound control and with (2) 20 μMHMA or (3) 20 μM amiloride. (B) MHVΔE re
HMA or (3) 20 μM amiloride. (C) HCoV229E in human MRC-5 cells. (1) No comhepatitis C virus (HCV) (Premkumar et al., 2004) and M protein
from Dengue (Premkumar et al., 2005). Such broad-spectrum
inhibition by HMA suggests that the drug-binding sites of these
channels from diverse viruses share structural similarities.
Another example of one compound inhibiting different ion
channels is amantadine, which blocks both influenza A M2
(Pinto et al., 1992; Sugrue and Hay, 1991), HCV p7 (Griffin
et al., 2003) and Dengue M protein channels (Premkumar et al.,
2005). HMA does not block the IBV E protein ion channel
suggestive of a more divergent structure of this group 3
coronavirus E protein. In this regard, models of the membrane
topology of the IBV and MHV E proteins are quite different
(Corse and Machamer, 2000; Maeda et al., 2001). The rectified
I–V plot observed in NaCl solutions (Fig. 4B) is also indicative
of unique properties of the IBV E protein channels that warrant
further investigation.
For some viral ion channels, like influenza A M2 and HIV-1
Vpu, ion channel activity is known to be important for virus
replication (reviewed in Fischer and Sansom, 2002; Gonzalez
and Carrasco, 2003). Amantadine's clinical use against
influenza A infections is the clearest evidence of this and the
mechanism of action of the M2 channel in virus replication has
been well characterized. We have shown that HMA – a blocker
of the Vpu ion channel– inhibits replication of HIV-1 in cultured
human primary macrophages (Ewart et al., 2004), but in this
case, the underlying mechanistic links remain to be uncovered.
In this manuscript, we report that in addition to blocking EVΔE replication in cultured cells. (A) MHV wild-type in mouse L2 cells. (1) No
combinant virus in mouse L2 cells. (1) No compound control and with (2) 20 μM
pound control and with (2) 20 μM HMA or (3) 20 μM amiloride.
303L. Wilson et al. / Virology 353 (2006) 294–306protein ion channels, HMA also inhibits replication of HCoV-
229E andMHV. Conversely, HMA at 20 μMdoes not inhibit the
recombinant virus, MHVΔE, with the entire E protein deleted
(see Figs. 6–8). Taken together, the data imply that the antiviral
target of HMA is the E protein, and further, that the E protein ion
channel activity is important for coronavirus replication. Other
groups have previously provided evidence for the importance of
E protein for replication of MHVand transmissible gastroenter-
itis coronavirus (TGEV), a group 1 coronavirus (Kuo and
Masters, 2003; Ortego et al., 2002). Deletion of the open reading
frame encoding the E protein from the genome ofMHVresults in
a strongly attenuated virus with a small plaque phenotype (Kuo
and Masters, 2003). This indicates that, while the E protein has
important roles in the MHV life cycle, it is not essential for in
vitro replication of MHV. In contrast, the E gene is thought to be
essential for replication of TGEV (Ortego et al., 2002).
HMA inhibited MHV replication in cultured cells with an
EC50 of 3.94 μM and the EC50 of HMA on MHV E protein ion
channel activity in planar lipid bilayers was calculated to be
10.2 μM. The two EC50s are in good agreement, particularly
given the vast differences in the physico-chemical environments
the channels are exposed to in the bilayer compared to infected
cells and the fact that membrane insertion and channel assembly
are not regulated by the same natural processes in the artificial
bilayer.
The E protein channels described here have different ion
selectivities (see Table 1), but all E proteins tested hitherto prefer
monovalent cations over chloride ions. The channel formed by
the HCoV-229E E protein (group 1 coronavirus) is about four
times more selective for K+ than Na+, while the channels from
MHV (group 2) and IBV (group 3) prefer Na+ ions. The two E
proteins from the group 2 coronaviruses tested thus far, MHV
and SARS-CoV (subgroups 2a and 2b, respectively) are themost
similar and have the highest selectivity for sodium. Others have
previously noted a relatively high degree of amino acid sequence
similarity between MHVand SARS-CoV E proteins, especially
in the TM domain (Shen et al., 2003). As more E protein
channels are characterized, it will be interesting to see how
the channel properties vary with sequence divergence and
whether ion selectivity properties co-segregate with taxo-
nomic groupings.
Complementation studies suggest that the E proteins from
coronavirus groups 2 and 3 may be functionally more similar
than for the group 1 E proteins. In a recombinant MHV (group
2) construct, the IBV E protein (group 3) – as well as the other
group 2 E proteins from bovine coronavirus and SARS-CoV –
could substitute for the MHV E protein and enhance replication
of the recombinant viruses. On the other hand, the TGEV
(group 1) E protein could not functionally replace the MHV E
protein (Lili Kuo and Paul Masters, personal communication).
In similar experiments, group 1 and group 2 E proteins were not
able to substitute for each other in the formation of heterologous
virus-like particles (VLPs) (Baudoux et al., 1998). It is possible
that the functional similarities and differences may be related to
the ion channel selectivities of the E protein channels, which we
found to be more similar between groups 2 and 3 E channels
(prefer Na+ ions) than group 1 (prefers K+ ions). Of course,more ion channel selectivity and complementation studies are
required to confirm these early observations.
In summary, the data presented here demonstrate that
coronavirus E proteins belong to the growing family of virus
ion channels. HMA blocks the HCoV-229E and MHV E protein
channels, which correlated with its ability to inhibit coronavirus
replication in cultured cells. Conversely, HMA did not affect
MHVΔE recombinant virus replication in cultured cells. Taken
together, the data suggest that E protein ion channel activity is
important for coronavirus replication and E protein blockers
could have potential anticoronaviral therapeutic use.
Materials and methods
Peptide synthesis and purification
Peptides were synthesized corresponding to the E protein
sequences from three coronaviruses in the GenBank database
(Table 3). The peptides were synthesized at the Biomolecular
Research Facility, John Curtin School of Medical Research, on
a SYMPHONY/MULTIPLEX (Protein Technologies inc.
Woburn, MS) multiple peptide synthesizer using FMOC
chemistry and solid phase peptide synthesis.
The full-length peptides were purified from any truncated
products using ProteoPLUS kit (Qbiogene, Inc., CA), following
manufactures instructions. Briefly, E peptides were dissolved in
loading buffer (60 mM Tris–HCl pH 8.3, 6 M urea, 5% SDS,
10% glycerol, 0.2% Bromophenol blue, and 100 mM β-
mercaptoethanol) and approximately 3 μg of the E peptides
were run with molecular weight markers (MBI Fermentas,
Hanover, MD) on a 4–20% gradient polyacrylamide gels
(Gradipore, NSW, Australia). The band corresponding to the
full-length peptides, of about 9.1, 9.7, or 10.5 kDa for HCoV-
229E, MHV, or IBV E proteins, respectively, were excised from
the gel, placed in a ProteoPLUS tube, and subjected to
electrophoresis. The purified peptides were dried in a Speedy-
Vac and resuspended in 2,2,2-trifluoroethanol (TFE). The
peptide concentration was determined by Bradford assay
(Pierce, Rockford, IL), following manufacturer's instructions.
Attempts to characterize the purified E peptides by Mass
spectrometry were unsuccessful, possibly due to the hydropho-
bic nature of the peptides.
Raising and purifying antibodies against HCoV-229E and
MHV E protein
Three synthetic peptides were also made for production of
antibodies recognizing the HCoV-229E and MHV E proteins.
The sequences of these shorter peptides are indicated as
underlined bold-face segments of the full-length sequences in
Table 3. The antigenic peptides were chemically synthesized
and coupled to a poly-lysine core via their terminal cysteine to
prepare multiple antigenic peptides (MAP) (Lu et al., 1991).
Individual, New Zealand White rabbits were immunized with
the MAP conjugated peptides with initial immunization of
200 μg peptide in Freund's complete adjuvant (Imject®, Pierce,
Rockford, IL). Boosters of 200 μg of peptide were given every
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304 L. Wilson et al. / Virology 353 (2006) 294–3062 weeks in Freund's incomplete adjuvant (Imject®, Pierce,
Rockford, IL), until sufficient antibody titers were attained.
About 15 ml of blood was collected from the ear vein 2, 4, 6, 8,
and 10 weeks post-immunization and antisera prepared.
Antiserum was assayed for antibody production by Western
blotting with the appropriate full-length E peptide. Epitope-
specific antibodies were purified from antisera by SulfoLink™
columns coupled to the equivalent peptide (Pierce, Rockford,
IL), following manufactures instructions.
Western blots
For Western blot analysis, samples were prepared in
loading buffer (60 mM Tris–HCl pH 8.3, 6 M urea, 5% SDS,
10% glycerol, 0.2% Bromophenol blue, and 100 mM β-
mercaptoethanol) and run with molecular weight markers
(MBI Fermentas, Hanover, MD) on 4–20% gradient poly-
acrylamide gels (Gradipore, NSW, Australia). Peptides were
transferred to polyvinylidene difluoride membranes (Invitro-
gen, Vic, Australia), using a semi-dry transfer apparatus (Amer-
sham Biosciences, Vic, Australia). Nonspecific sites were
blocked with skim milk proteins in Tris-buffered saline
containing 1% Tween-20. Peptides were detected with purified
primary antibody to HCoV-229E E protein TM domain C-
terminal (anti-HCoV-229E E); MHV E protein N-terminal
antibody (anti-MHV EN); and IBV E protein anti-C-terminal
antibody (anti-IBV EC) (Corse and Machamer, 2000) (kind
gift from Carolyn Machamer, John Hopkins University, Balti-
more). The primary antibodies were detected with goat anti-
rabbit IgG alkaline phosphatase-conjugated antibody (Dako,
NSW). Color development was visualized with Western blue-
stabilized substrate for alkaline phosphatase (Promega, NSW,
Australia).
Ion channel recording
The purified HCoV-229E, MHV, and IBV E proteins were
resuspended to 1 mg/ml in TFE and their ability to form ion
channels was tested on aWarner bilayer rig (Warner instruments,
Inc. 1125 Dixwell Avenue, Hamden, CT 06514), as described
previously (Wilson et al., 2004). Briefly, a lipid mix of 3:1:1 1-
palmitoyl-2-oleolyl phosphatidyl ethanolamine:1-palmitoyl-2-
oleolyl phosphatidyl serine:1-palmitoyl-2-oleolyl phosphatidyl
choline in chloroform were dried under N2 gas and resuspended
in n-decane. Bilayers were painted across a circular hole of
approximately 100 μm diameter in a Delrin cup separating
aqueous solutions in the CIS and TRANS chambers. For testing
E protein selectivity for Na+ and Cl− ions, the solution in the CIS
chamber consisted of 500 mM NaCl, and 5 mM HEPES (pH
7.2), while the solution in the TRANS chamber contained
50 mM NaCl and 5 mM HEPES (pH 7.2). For testing E protein
selectivity for K+ and Cl− ions, the solution in the CIS chamber
consisted of 500 mMKCl and 5 mMHEPES (pH 7.2), while the
solution in the TRANS chamber contained 50 mM KCl and
5 mMHEPES (pH 7.2). Currents were amplified using aWarner
model BD-525D amplifier with sampling rate of 5 kHz and
filtered at 1 kHz before being digitally recorded directly using
305L. Wilson et al. / Virology 353 (2006) 294–306the Data Collect software developed by Mr. Bernie Keys
(BioResearch Electronics, Canberra, Australia).
Small aliquots (about 3 μg) of the E peptides dissolved in
TFE were added to the CIS chamber, while stirring to facilitate
spontaneous insertion of the hydrophobic peptides into the lipid
bilayer. Typically, when present, ion channel activity was
detected after about 5–15 min of stirring. The CIS chamber was
earthed and the TRANS chamber was held at a range of
potentials between +100 mV to −100 mV. The voltage (Vm) vs.
the current (I) were plotted (I–V plot) to determine the reversal
potential (Vr), which indicates the ion selectivity of the channel.
The theoretical Vr for a Na
+ or K+ selective channel in our
experimental set up was +54 mV, whereas the theoretical Vr for
a Cl− channel was −54 mV (using activities in the Nernst
equation). The Vr was used in the Goldman–Hodgkin–Katz
(GHK) equation to determine the relative permeability ratios
(PNa+/PCl− or PK+/PCl−) of the ion channel.
Epitope-specific antibody inhibition of E protein ion channel
activity
To determine antibody blocking, after ion channel activity
was detected, affinity-purified polyclonal antibody was added
to the CIS or TRANS chamber to a final concentration of
about 50–100 μg/ml, while stirring for 30 s. Bilayer currents
were recorded before ion channel formation, after ion chan-
nel formation, and after the addition of the purified anti-
body. A T test (Microsoft Excel) was used to determine if
there was significant difference between the mean current
recorded before and after addition of the epitope-specific
antibody.
Affinity purified anti-HCoV-229E E and anti-MHV E47–67
antibodies were used to immunoprecipitate the HCoV-229E and
MHV E proteins, respectively, using the Seize X protein A
immunoprecipitation kit (Pierce, Rockford, IL), following
manufactures instructions. Briefly, the antibodies were bound
and cross-linked to protein A column and 1 mg/ml of
corresponding E protein was immunoprecipitated, from the
solution. The flow-through, which should not contain any E
protein, and eluate, which contains the immunoprecipitated
E protein were analyzed by Western blot. The HCoV-229E
and MHV E protein flow-through were tested for their abi-
lity to form ion channels in planar lipid bilayers as described
above.
Amiloride derivative inhibition of E protein ion channels
Stock solutions of amiloride and HMA (Sigma, Australia) at
50 mM were prepared in 50% DMSO:50% methanol. To
determine if the amiloride derivatives blocked the E proteins ion
channel conductance in planar lipid bilayers, after ion channel
currents were detected, 100–200 μM of compound was added
to the CIS chamber while stirring to facilitate binding of the
compound to the channel. The current across the bilayer was
recorded prior to addition of the E protein, after detection of ion
channel conductance, and after addition of the compound. A T
test (Microsoft Excel) was used to test the difference betweenthe normalized mean currents before and after addition of the
compounds.
Viruses and cells
Mouse L2, L929, and 17Cl1 cells lines (ATCC) were grown
in DMEM (Invitrogen, Vic, Australia) supplemented with 10%
FCS (Invitrogen, Vic, Australia). MHV-A59 (ATCC) and MHV
with the entire E protein deleted (referred to as MHVΔE) (kind
gift from Paul Masters, Wadsworth centre, Albany), were
amplified in 17Cl1 cells. The MHV wild-type and MHVΔE
recombinant virus were plaque assayed in L2 cells with plaque
overlay for observation of plaque phenotype or assayed in L929
cells without overlay for the easy counting of plaque numbers.
Human MRC-5 cell lines (ATCC) were grown in DMEM
(Invitrogen, Vic, Australia) supplemented with 10% FCS
(Invitrogen, Vic, Australia). The HCoV-229E (ATCC) was
two times plaque purified in MRC-5 cells and plaque assayed in
MRC-5 cells with plaque overlay.
Antiviral plaque assay
For determining if HMA or amiloride had antiviral activity on
MHVand for calculating the compounds EC50 the plaque assay
was done in L929 cells, without plaque overlay. MHV infection
in L929 cells without plaque overlay results in the newly
emerged plaques disseminating from the original infected cell
and starting a new plaque. Therefore, in the presence of antiviral
compound, there is a reduction in plaque number, which can
easily be counted. The L929 cells were infected withMHVwild-
type at a multiplicity of infection (MOI) 0.01 for 1 h at 37 °C in
5% CO2, then 10 μM, 7.5 μM. 5 μM, 2.5 μM, 1.25 μM,
0.625 μM, 0.3125 μM, or 0 μM of amiloride or HMA were
added. After 24-h incubation at 37 °C in 5% CO2, the culture
media were removed, and the cells were stained with 0.1%
crystal violet in 20%methanol. The plaque number per well was
counted, and the percent reduction was calculated from the no
compound control. The compound concentration was plotted
against the percent reduction in plaques, and the EC50 was
calculated from the equation of the line.
The plaque phenotype of MHV wild-type or MHVΔE in the
presence or absence of antiviral compound was studied in mouse
L2 cells with plaque overlay (1% Seaplaque in MEM, 10%
FCS). The L2 cells were plated in 6-well plates and grown to
confluence, then infected with MHV wild-type at a MOI of 0.01
or MHVΔE (MOI 0.1) for 1 h. Higher MOI of MHVΔE was
used so that the number of plaques per well were comparable
between the MHV wild-type and MHVΔE, which has a lower
titration. After 1-h incubation, the virus was removed and
replaced with 1% seaplaque overlay inMEM supplemented with
10% FCS and 20 μM or 0 μM (no compound control) of test-
antiviral compound dissolved in 50% DMSO: 50% methanol.
After 48-h incubation at 37 °C in 5% CO2, the cells were stained
with 0.1% crystal violet in 20%methanol and the average plaque
size determined.
HCoV-229E was plaque assayed in humanMRC-5 cells. The
MRC-5 cells were grown to confluence in 6-well plates and
306 L. Wilson et al. / Virology 353 (2006) 294–306then infected with HCoV-229E at a MOI of 0.01 for 1 h at 35 °C
in 5% CO2. After 1-h incubation 5 μM, 2.5 μM, 1 μM or 0 μM
(no compound control) of test-antiviral compound dissolved in
50% DMSO: 50% methanol was added to each well. The assay
was incubated for 6 days at 35 °C in 5% CO2, until plaques were
visible and then stained with 0.1% crystal violet in 20%
methanol.
The concentrations of the compounds used in the antiviral
assays were not significantly toxic as determined by the MTT
cytotoxicity assay (Sigma, Australia), following manufactures
instructions. Note, that for the MRC-5 cells the compounds
were found to be considerable more toxic, which is most likely
due to the elongated nature of the MRC-5, resulting in greater
absorbance of the compounds. Therefore, the amiloride
derivatives in the HCoV-229E plaque assay were used at a
lower concentration, which was not toxic for the MRC-5 cells.
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